ERT, Bioclinica Rebrand As Clario

November 3, 2021 | ERT today announced that following its early Q2 merger with Bioclinica, the combined company is renamed Clario. 

Clario positions itself as a technology company that generates the richest clinical evidence by fusing scientific expertise and global scale into the broadest endpoint technology platform. Clario is committed to innovating the future of clinical trials through technology and having a positive impact on global healthcare.

With almost 50 years of experience, Clario generates reliable evidence needed to bring new medicines, medical devices and therapies to market. Clario’s scientific, regulatory, engineering, and operations expertise guides clinical trial partners through every phase of clinical development. Led by over 200 therapeutic area experts, Clario delivers innovative therapeutic area technology solutions to meet clinical trial objectives. 

Clario offers Trial Anywhere, the ability to execute decentralized, hybrid and site-based clinical trials by deploying technology while maintaining the precision and reliability of evidence. Trial Anywhere offers sites and sponsors more clinical trial options, empowers patient choice, and provides the means to create diversity within clinical trials improving health equity.

"Clario is much more than the merger of two companies," said CEO Joe Eazor in a press release today. "We have combined decades of scientific expertise and unrivaled global scale to create the broadest endpoint technology platform poised to expedite the clinical trial process, simplify trial experiences and unlock composite endpoints. Our purpose is clear—we transform lives by unlocking better evidence.” 

Since 1990, the companies that are now Clario have completed more than 19,000 clinical trials and contributed to 870 regulatory approvals. Between 2019 and 2020 alone, the groups supported 70% of all Federal and Drug Administration (FDA) approvals. 

The new name and brand identity became effective on Nov. 3, 2021. Learn more at Clario.com.

 

 

Load more comments
comment-avatar